For decades, pharmaceutical manufacturing decisions have largely been driven by a familiar set of considerations: quality, technical capability, capacity, and cost.
While these factors remain fundamental, the criteria sponsors use to evaluate manufacturing strategies are evolving. Increasingly, pharmaceutical companies are placing greater emphasis on supply continuity, operational flexibility, and long-term resilience. As a result, U.S. manufacturing has become an increasingly important part of strategic manufacturing discussions, not simply because of recent market developments, but because many organizations recognize the role U.S.-based manufacturing can play in supporting reliable supply and long-term commercial success.
This shift reflects broader changes across the pharmaceutical industry. Supply chains have become more interconnected, product portfolios more complex, and commercialization timelines more demanding. Sponsors are often managing multiple external partners, navigating evolving regulatory expectations, and preparing for changing commercial needs simultaneously. In this environment, manufacturing strategy is no longer viewed solely as an operational decision. It has become an important component of broader business planning, influencing an organization’s ability to respond to change while maintaining quality, continuity, and execution.
The size of the U.S. market also influences these decisions. As the world’s largest pharmaceutical market, the United States remains a primary commercial destination for many therapies. Manufacturing closer to end-market demand can help streamline distribution, strengthen supply chain reliability, and improve responsiveness as commercial needs evolve. For many sponsors, U.S.-based manufacturing is therefore evaluated not only for operational capabilities, but also for its ability to support long-term commercial strategy.
Bora has long recognized the strategic value of U.S. manufacturing. The company’s continued investment in U.S. manufacturing capabilities reflects a long-term commitment to helping customers build more resilient supply chains, strengthen operational flexibility, and support reliable delivery of critical therapies. While industry priorities continue to evolve, these investments have remained focused on creating integrated manufacturing solutions that help sponsors navigate increasingly complex development and commercialization pathways.
Looking beyond cost and capacity
Manufacturing capacity remains an important consideration when evaluating a manufacturing strategy, but capacity alone does not determine long-term success. Sponsors must also evaluate whether a manufacturing network can consistently support process requirements, analytical methods, quality expectations, technology transfer activities, and future commercial demand without introducing unnecessary complexity.
For complex products, particularly those approaching commercialization, successful execution depends on more than available production space. Equipment compatibility, workforce expertise, analytical capabilities, quality oversight, and commercialization experience all influence whether a manufacturing partner can support reliable execution throughout the product lifecycle.
Each of these factors contributes to manufacturing performance in different ways. Equipment and process compatibility can reduce the need for unnecessary redevelopment as products scale. Experienced technical teams are often better positioned to anticipate manufacturing challenges before they affect timelines.
Mature analytical and quality capabilities help support consistent execution throughout development, validation, and commercial manufacturing. Evaluating these capabilities early provides sponsors with a more complete understanding of a manufacturing partner’s ability to support both immediate program needs and long-term growth.
The role of U.S. manufacturing in supply continuity
As supply chains become increasingly complex, many organizations are reassessing how manufacturing location contributes to long-term continuity. For products intended for the U.S. market, manufacturing closer to where therapies will ultimately be distributed can provide advantages beyond geographic proximity. U.S.-based manufacturing can support closer collaboration between development and manufacturing teams, improve operational visibility and cross-functional coordination, and strengthen supply reliability for products intended for the world’s largest pharmaceutical market.
These benefits often become most apparent as programs evolve. Products rarely follow a perfectly predictable path from development through commercialization. Demand forecasts may change, manufacturing requirements may evolve, and organizations frequently need to make strategic decisions while balancing quality, timelines, and commercial objectives. Manufacturing strategies that emphasize coordination and flexibility are generally better positioned to adapt to these changes while maintaining continuity.
For many sponsors, U.S.-based manufacturing can also simplify communication across technical, quality, regulatory, and operational teams. Shorter communication pathways and closer organizational alignment can help facilitate faster decision-making, improve issue resolution, and strengthen collaboration throughout development, technology transfer, and commercial manufacturing.
This perspective reflects a broader shift in how pharmaceutical companies evaluate manufacturing strategies. Rather than focusing exclusively on individual facilities or production capacity, organizations are increasingly considering how manufacturing networks support continuity throughout the product lifecycle. Integrated capabilities, coordinated project management, and reduced operational complexity all contribute to manufacturing strategies that are better positioned to adapt as commercial priorities evolve.
What resilience looks like in practice
Resilience has become one of the pharmaceutical industry’s most frequently discussed priorities, but it extends beyond simply responding to disruptions. In practice, resilience is the ability to adapt as business needs change while continuing to deliver products reliably, maintain quality standards, and support patients without unnecessary interruption.
Building resilience requires thoughtful planning across the manufacturing lifecycle. It means establishing processes that can accommodate evolving commercial demand, maintaining strong communication between technical and operational teams, and creating manufacturing strategies that can respond efficiently to changing circumstances. Rather than eliminating every potential challenge, resilient organizations focus on reducing complexity, improving visibility, and strengthening coordination so that inevitable changes can be managed more effectively.
Integrated manufacturing models support this objective by bringing development, analytical services, technology transfer, manufacturing, packaging, and quality functions into a coordinated operating framework. When these capabilities work together, organizations can often reduce unnecessary handoffs, improve communication between cross-functional teams, and streamline execution across development and commercial programs.
As products progress toward commercialization, this level of coordination can improve predictability while helping organizations identify potential challenges earlier. Strong collaboration does not eliminate complexity, but it can make manufacturing programs more adaptable and better positioned to support long-term continuity.
Manufacturing strategy as a long-term business decision
Historically, manufacturing discussions often centered on identifying available capacity or selecting a facility capable of producing a particular product. While those considerations remain important, today’s decisions increasingly reflect broader business objectives.
Organizations are evaluating whether manufacturing strategies can support future growth, accommodate changing market conditions, and provide the flexibility needed as product portfolios evolve. Questions surrounding operational alignment, network capabilities, and long-term scalability have become increasingly important alongside traditional considerations such as cost and production capacity.
As a result, manufacturing strategy is becoming less about solving immediate production needs and more about building a foundation for sustained commercial success. The decisions made today can influence an organization’s ability to respond to future opportunities, support changing business priorities, and maintain reliable supply over the life of a product.
Planning for long-term manufacturing flexibility
As pharmaceutical companies continue evaluating manufacturing strategies, flexibility has become an increasingly important consideration alongside quality, capacity, and cost. Manufacturing networks should be capable of adapting as programs evolve, commercial demand changes, and new opportunities emerge. This requires thoughtful planning, strong operational foundations, and manufacturing partners that can support both current and future business objectives.
For Bora, continued investment in U.S.-based manufacturing reflects this long-term perspective. By combining U.S. manufacturing capabilities with integrated development, analytical, technology transfer, and commercial manufacturing services, Bora helps sponsors build manufacturing strategies designed to support continuity, operational flexibility, reliable execution throughout the product lifecycle, and reliable supply to the world’s largest pharmaceutical market.
Ultimately, U.S.-based manufacturing is no longer simply a question of where products are made. For many pharmaceutical companies, it has become an important component of broader manufacturing and commercial strategy. As supply chains continue to evolve and the United States remains the world’s largest pharmaceutical market, organizations are placing greater emphasis on manufacturing networks that support resilience, adaptability, and reliable supply for long-term commercial success. Sponsors that evaluate manufacturing decisions through this broader strategic lens will be better positioned to navigate future challenges while maintaining reliable supply and supporting patient needs.